Sustained Hepatitis B Surface Antigen Loss In Chronic Hepatitis B Patients With Subcutaneous Pd-L1 Antibody Asc22 Treatment: Interim Results Of Phase Iib Study
Hangzhou, China And Shaoxing, China, Nov. 8, 2021 /Prnewswire/ -- Ascletis Pharma Inc. (Hkex: 1672) Announces Today That The Interim Results Of 44 Chronic Hepatitis B (Chb) Patients From A Phase Iib Trial Of Asc22 (Envafolimab), A Subcutaneously Administered Pd-L1 Antibody (Clinicaltrials.Gov Identifier: Nct04465890), Demonstrated Sustained Hbsag Loss In Chb Patients With Baseline Hbsag ? 500 Iu/Ml. The Result Abstract Has Been Selected For Oral Presentation In Late Breaking Session At The Liver Meeting
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
